Key statistics
As of last trade Neuronetics Inc (NRC:DUS) traded at 1.09, 6.84% above its 52-week low of 1.02, set on Feb 24, 2026.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 1.09 |
|---|---|
| High | 1.09 |
| Low | 1.09 |
| Bid | 1.07 |
| Offer | 1.11 |
| Previous close | 1.16 |
| Average volume | 0.00 |
|---|---|
| Shares outstanding | 68.49m |
| Free float | 55.39m |
| P/E (TTM) | -- |
| Market cap | 91.77m USD |
| EPS (TTM) | -0.8344 USD |
Data delayed at least 15 minutes, as of Mar 02 2026 07:12 GMT.
More ▼
- TRICARE West Expands NeuroStar® TMS Coverage to Include Adolescents Aged 15+ Struggling with Depression
- Neuronetics Announces Three-Year Exclusive Partnership with Elite DNA Behavioral Health to Expand NeuroStar Access and Operational Excellence
- New York State Medicaid Expands Coverage for TMS Therapy, Including NeuroStar® Advanced Therapy, to Treat Major Depressive Disorder (MDD)
- NeuroStar Announces New Publication in JAACAP Open Highlighting Treatment Efficacy in Depressed Adolescents
- Neuronetics Announces Clinical Presence at the 2025 Clinical TMS Society Annual Meeting and Progress in Greenbrook’s Personalized Care Trial Program
- Neuronetics Launches First Inaugural National TMS Therapy Awareness Day During Mental Health Awareness Month
- Evernorth Health Services, a Cigna Company, Expands NeuroStar® TMS Coverage for Adolescents Struggling with Depression
More ▼
